Zimmer Biomet Holdings Azioni (NYSE: ZBH)

Zimmer Biomet Holdings (NYSE:ZBH) Azioni

ZIMMER BIOMET HOLDINGS INC

Zimmer Biomet Holdings

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings Inc

Treace Medical Concepts, Inc.&nbsp;("Treace" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship&nbsp;<a href="https://www.globenewswire.com/Tracker?data=PhrvPgwWnFGurg6S4cTMXPnZSvIbsh-7vD75qshZf4W2Rv0eH6iYS-TAky5-84_Ri0VIN7nTuV0z-GkegYiluBakImmk3Zj1w4rROHMt6lwsw3REO81rw-etukNCmXZSin4tSCCkNkE0xBHrq0Q7tPjokuA-oap_BjbHuXsRo-LgNNZoGsnUePUbT2-ILzChf2DHLwrSQXQZyWVQvrJEbk0AQHM7eVsk7zC4vaKtqUoeoDHCJzOqPhWKcqtvWnTInYG_aeXX0i81qxfMgqiVsg==">Lapiplasty</a><a href="https://www.globenewswire.com/Tracker?data=LrnJlF18b7EWzk_EAUJaWxGrxsoWgQpX1WKeJ0MipgVBshUVXHUA5zPh5NCDgcNKBO6A9xD35YFbiyZ1DNTulkO1cYzusFeKbXuLEM4blCZJ5k744h9h6kzAVfgox0FPgavIE7DwiF422KNrSWJFHx01V7TfoKgoah7rt5AC07IhZmYAf7CbRDc1QqTt8wwbr56hBQaud9XD_58LlCi_nMcPOnTeqG5Lb_IyWD8AxttJPAbLBRIxrVfgQTACvnytyRl4MFQiNTFTY4mRBRbg-Q==">&#xAE;</a>&nbsp;and&nbsp;<a href="https://www.globenewswire.com/Tracker?data=Ky8kGGLXsMTu3wsAXQppn1PfeewfClEbXAZbmmoTmTGzckwETGDKjrRCVtjW_PfjE682okBcjHwSpyYD3ZLTWqlyvmlQaTncmuRanfcgyPXq89flAjVvT8U90c9JXN3ZHl_RVYLNeeXD1fy3lK0reILVhp40trP0SNtWir-Im2LoRiGF6hZmEkTIaoQWpTaJNiiAU3_p36gcE7q72b6FYhsIHMJpXu4rMIRqg6AB3B4p9xhKAjU7aR8hF3ED29goR3-pfMcJotTJpuPXNubY4swADMFv4kvo1u9e-PuH6H034oUlBGOBo8pbqcqr6pHY">Adductoplasty</a><a href="https://www.globenewswire.com/Tracker?data=iU3fmGaUZi_JeR470Lioedud-n-0b_bx4qOO-3b22Rvo4Xdt1yz_PqYHunQivstC8HxZtcFDnANwN5nPFT05HigJ0nSJBwn0LnMVL0ugniZAkJRYpK-63l0Qn7aWa0elJwsd5hZielGaxqcGOfBP6MtE2xeJMav5md3UhP8ioZkA0CQNWbieFy6sUjXGNl9yCVNuhlpeg58_DWgp2zGQCrNi8j1JTY2kOFmxR0GJ6TFclq7OrROrzjUrDqYhpUNd3NzdJg9mJf7bHMrBObB4dtCB4BQHRme_eeVBW5QPZ4w=">&#xAE;</a>&nbsp;procedures, today announced that it filed a lawsuit against&nbsp;Zimmer Biomet Holdings, Inc. and Paragon 28, Inc. (collectively, "Zimmer") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>), alleging infringement of 4 patents related to Treace's innovative Lapiplasty&#xAE; 3D Bunion Correction&#xAE; technologies. The suit was filed in the&nbsp;United States District Court for the District of Delaware, and seeks injunctive relief and damages.

Biotech

News

General

TMCI

Treace Medical Concepts Files Patent Infringement Lawsuit Against Zimmer Biomet And Paragon 28, Alleging Violation Of 4 Patents Related To Its Lapiplasty 3D Bunion Correction Technologies And Seeking Injunctive Relief And Damages

Zimmer Biomet Appoints Kevin Thornal As Group President, Global Businesses And Americas, Effective July 1, 2025

Ratings for Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $107.4, a high estimate of $125.00, and a low estimate of $95.00. A 13.6% drop is evident in the current average compared to the previous average price target of $124.30. 
<img src="https://www.benzinga.com/files/images/story/2025/1747058418_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Zimmer Biomet Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$101.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$104.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$104.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$115.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$112.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Cecilia Furlong</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$95.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$98.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Zimmer Biomet Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Zimmer Biomet Holdings compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Zimmer Biomet Holdings's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Zimmer Biomet Holdings's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ZBH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Zimmer Biomet Holdings analyst ratings.</a>
<h2>All You Need to Know About Zimmer Biomet Holdings</h2>
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
<h3>Unraveling the Financial Story of Zimmer Biomet Holdings</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Zimmer Biomet Holdings's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1.05% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Zimmer Biomet Holdings's net margin is impressive, surpassing industry averages. With a net margin of 9.53%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Zimmer Biomet Holdings's ROE stands out, surpassing industry averages. With an impressive ROE of 1.46%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.84%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.58, Zimmer Biomet Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Assessing Zimmer Biomet Holdings: Insights From 10 Financial Analysts

Canaccord Genuity analyst William Plovanic maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Hold and lowers the price target from $115 to $101.

Price Target

Canaccord Genuity Maintains Hold on Zimmer Biomet Holdings, Lowers Price Target to $101

JMP Securities analyst David Turkaly maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Market Outperform and lowers the price target from $140 to $125.

JMP Securities Maintains Market Outperform on Zimmer Biomet Holdings, Lowers Price Target to $125

Zimmer Biomet Holdings, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) reported better-than-expected earnings for the <a href="https://www.benzinga.com/quote/ZBH">first quarter on Monday</a>.
The company posted first-quarter adjusted EPS of $1.81, down from $1.94 a year ago, beating the Street estimates of $1.77. The orthopedic giant reported sales of $1.91 billion, up 1.1% on a reported basis (+2.3% on constant currency), almost in line with the consensus of $1.9 billion.
&#8220;We are proud of our team&#8217;s continued execution and performance to start the year, as we delivered solid first quarter results and advanced our bold innovation agenda,&#8221; said Ivan Tornos, Zimmer Biomet&#8217;s President and Chief Executive Officer.
The company expects fiscal year 2025 adjusted EPS of $7.90-$8.10, down from prior guidance of $8.15-$8.35 versus consensus of $8.19.
The company expects 2025 revenue growth of 5.7% – 8.2% compared to 1%-3.5% expected earlier. It expects a foreign currency exchange impact of 0.0%-0.5%.
Zimmer Biomet shares gained 0.7% to trade at $91.08 on Tuesday.
These analysts made changes to their price targets on Zimmer Biomet following earnings announcement.
<ul>
<li>Baird analyst Jeff Johnson maintained Zimmer Biomet Holdings with an Outperform rating and lowered the price target from $130 to $115.</li>
<li>Wells Fargo analyst Larry Biegelsen maintained the stock with an Equal-Weight rating and lowered the price target from $113 to $98.</li>
<li>JP Morgan analyst Robbie Marcus maintained the stock with an Overweight rating and lowered the price target from $128 to $105.</li>
<li>Morgan Stanley analyst Cecilia Furlong maintained the stock with an Equal-Weight rating and lowered the price target from $115 to $95.</li>
<li>RBC Capital analyst Shagun Singh maintained Zimmer Biomet with an Outperform and lowered the price target from $125 to $112.</li>
<li>Stifel analyst Rick Wise maintained Zimmer Biomet with a Buy and lowered the price target from $138 to $115.</li>
<li>Raymond James analyst Jayson Bedford maintained Zimmer Biomet with an Outperform rating and lowered the price target from $119 to $104.</li>
<li>Goldman Sachs analyst David Roman maintained the stock with a Neutral and lowered the price target from $120 to $104.</li>
</ul>
Considering buying ZBH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="619" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06142102/image-56-1024x619.png" alt="" class="wp-image-904113" style="width:549px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06142102/image-56-1024x619.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06142102/image-56-300x181.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06142102/image-56-768x464.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06142102/image-56.png 1105w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more">Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a> </li>
</ul>
Photo via Shutterstock

Earnings

Markets

Trading Ideas

These Analysts Lower Their Forecasts On Zimmer Biomet After Q1 Results

Goldman Sachs analyst David Roman maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Neutral and lowers the price target from $120 to $104.

Goldman Sachs Maintains Neutral on Zimmer Biomet Holdings, Lowers Price Target to $104

Raymond James analyst Jayson Bedford maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Outperform and lowers the price target from $119 to $104.

Raymond James Maintains Outperform on Zimmer Biomet Holdings, Lowers Price Target to $104

Stifel analyst Rick Wise maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Buy and lowers the price target from $138 to $115.

Stifel Maintains Buy on Zimmer Biomet Holdings, Lowers Price Target to $115

RBC Capital analyst Shagun Singh maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Outperform and lowers the price target from $125 to $112.

RBC Capital Maintains Outperform on Zimmer Biomet Holdings, Lowers Price Target to $112

Morgan Stanley analyst Cecilia Furlong maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Equal-Weight and lowers the price target from $115 to $95.

Morgan Stanley Maintains Equal-Weight on Zimmer Biomet Holdings, Lowers Price Target to $95

Zimmer Biomet Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) short percent of float has fallen 11.44% since its last report. The company recently reported that it has 6.28 million shares sold short, which is 3.64% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.36 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Zimmer Biomet Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746543621_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Zimmer Biomet Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Zimmer Biomet Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Zimmer Biomet Holdings's peer group average for short interest as a percentage of float is 4.18%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Zimmer Biomet Holdings?

JP Morgan analyst Robbie Marcus maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Overweight and lowers the price target from $128 to $105.

JP Morgan Maintains Overweight on Zimmer Biomet Holdings, Lowers Price Target to $105

Wells Fargo analyst Larry Biegelsen maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Equal-Weight and lowers the price target from $113 to $98.

Wells Fargo Maintains Equal-Weight on Zimmer Biomet Holdings, Lowers Price Target to $98

Baird analyst Jeff Johnson maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Outperform and lowers the price target from $130 to $115.

Baird Maintains Outperform on Zimmer Biomet Holdings, Lowers Price Target to $115

Zimmer Biomet Holdings, Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) reported first-quarter adjusted EPS of $1.81, down from $1.94 a year ago, beating&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the Street estimates of $1.77</a>.
The orthopedic giant reported sales of $1.91 billion, up 1.1% on a reported basis (+2.3% on constant currency), almost in line with the <a href="https://www.benzinga.com/pressreleases/25/05/n45189888/zimmer-biomet-announces-first-quarter-2025-financial-results" target="_blank" rel="noreferrer noopener">consensus of $1.9 billion</a>.
<ul>
<li>Knee product sales increased 0.6% to $792.9 million (+1.9%), and hip product sales increased 0.9% (+2.4% on constant currency) to $495.8 million.</li>
<li>Sports Medicine products generated sales of $470.5 million, up 3.9% (+4.9%).</li>
<li>Technology &amp; Data, Bone Cement, and Surgical sales fell 4.7% (-3.5%) to $149.9 million.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44652075/us-tariffs-spare-drugmakers-but-threaten-diabetes-device-industry" rel="noreferrer noopener">Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry</a>
Operating margin improved to 15.3% from 14.1%.
Ivan Tornos, Zimmer Biomet&#8217;s President and CEO, addressed &#8220;the recently completed <a href="https://www.benzinga.com/pressreleases/25/04/n44896156/zimmer-biomet-completes-acquisition-of-paragon-28" target="_blank" rel="noreferrer noopener">acquisition of Paragon 28</a>.&#8221; The company also updated its full-year 2025 reported revenue guidance to include tariff proposals and <a href="https://www.benzinga.com/news/guidance/25/01/43297796/zimmer-biomet-snaps-up-paragon-28-in-1-2-billion-deal-details" target="_blank" rel="noreferrer noopener">currency expectations</a>.
The company expects fiscal year 2025 adjusted EPS of $7.90-$8.10, down from <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43539408/why-is-zimmer-biomet-stock-trading-lower-on-thursday" rel="noreferrer noopener">prior guidance of $8.15-$8.35</a> versus consensus of $8.19.
The company expects 2025 revenue growth of 5.7% &#8211; 8.2% compared to 1%-3.5% expected earlier.
It expects a foreign currency exchange impact of 0.0%-0.5%.
In March, the U.S. Food and Drug Administration (FDA) granted 510(k) clearance to Persona&nbsp;Revision SoluTion Femur, a revision knee implant&nbsp;component offering an alternative for patients with sensitivities to certain metals. Persona Revision SoluTion Femur will be commercially <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44187963/zimmer-biomet-receives-fda-clearance-for-persona-revision-solution-femur" rel="noreferrer noopener">available in the U.S. in Q3 2025</a>.
In April, Zimmer Biomet&#8217;s RibFix Advantage Fixation System received CE Mark certification – the first CE Mark for an <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44582315/zimmer-biomet-receives-ce-mark-approval-for-ribfix-advantage-fixation-system" rel="noreferrer noopener">intrathoracic rib fixation system</a>.
Price Action:&nbsp;ZBH stock is down 9.57% at $92.59&nbsp;at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45196924/neurology-focused-axsome-therapeutics-clocks-around-60-topline-growth-in-q1-commercial-availability-of-newly-approved-migraine-drug-expected-in-june" target="_blank" rel="noreferrer noopener">Axsome Therapeutics Clocks Around 60% Topline Growth In Q1</a></li>
</ul>

Large Cap

Guidance

Health Care

Movers

Hip Implant Maker Zimmer Biomet Cuts Annual Profit Forecast On Paragon 28 Deal

Wall Street kicked off the week with a cautious tone, as major stock indices hovered near the flatline by midday in New York. Investors digested fresh signs of inflationary pressure in the services sector, raising doubts about near-term rate cuts and <a href="https://www.benzinga.com/markets">weighing on risk appetite.</a>
The ISM Services PMI for April pointed to only marginal growth, the slowest since late 2023, while the index for prices paid surged to its highest reading in more than two years, reflecting a sharp rise in input costs amid renewed trade disruptions tied to tariffs announced last month by President Donald Trump.
The S&amp;P 500 slipped 0.2% to 5,670, while the Nasdaq 100 matched the decline to 20,050. The Dow Jones Industrial Average, however, managed a modest 0.2% gain. If the S&amp;P 500 closes higher, it would mark its tenth consecutive session of gains, the longest winning streak since September 1995.
Rising bond yields pressured equities, with the 10-year Treasury yield climbing 4 basis points to 4.35%, and the 30-year yield up at 4.83%.
Speaking at the Milken Institute, Treasury Secretary Scott Bessent said the U.S. was nearing agreements on new trade deals, potentially as soon as this week. He indicated that 17 trading partners, excluding China, had presented strong proposals, and suggested that meaningful progress with China could also emerge in the coming weeks.
Meanwhile, oil prices dropped 2% to $57 a barrel following OPEC+'s signal of a 411,000 bpd production hike starting in June, with further increases possible over the summer.
Gold rallied 2%, on track for its strongest session in two weeks, while Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) held steady near $94,000.
<h3 class="wp-block-heading">Monday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg %</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>41,418.85</td>
<td>+0.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,677.19</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,016.46</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,057.89</td>
<td>-0.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:42 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched 0.2% down to $565.72.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.3% to $414.11.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;fell 0.2% to $487.66.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) inched 0.1% lower to $200.11.</li>
<li>The&nbsp;Industrials&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>) outperformed, up 0.6%; the&nbsp;Energt Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 1.4%.</li>
</ul>
<h3 class="wp-block-heading">Monday&#8217;s Stock Movers</h3>
Stocks reacting to earnings reports included: 
<ul>
<li>Berkshire Hathaway Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) down 4.26%</li>
<li>Cummins Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) up 2.07%</li>
<li>Tyson Foods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) down 7.63%</li>
<li>Zimmer Biomet Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) down 9.28%</li>
<li>Loews Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/L#NYSE">L</a>) down 1.29%</li>
<li>ON Semiconductor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) down 8.17%</li>
<li>Henry Schein Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) up 0.86%</li>
</ul>
Stocks scheduled to report earnings after the close include Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), The Clorox Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>), Coterra Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>), Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), Diamondback Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>), Realty Income Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/O#NYSE">O</a>), The Williams Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>), Celanese Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>), Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>), Lattice Semiconductor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>), Mattel Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>) and Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>).
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45198741/goldman-sachs-issues-bearish-40-oil-forecast-as-opec-pumps-more-energy-stocks-sink">Goldman Sachs Issues Bearish $40 Oil Forecast As OPEC+ Pumps More: Energy Stocks Sink</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Equities

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

Economics

Tech

ETFs

$BTC

CTRA

SPDR Dow Jones Industrial Average ETF Trust

FANG

HSIC

LSCC

PLTR

VRTX

Select Sector SPDR-Consumer Discretionary

Stocks Pause Gains As Treasury Yields Rise: What's Driving Markets Monday?

The U.S. services sector grew at its slowest pace in over 17 months in April, while inflationary pressures surged to an over two-year high, highlighting a troubling combination of weakening demand and rising costs fueled by trade tariff disruptions that could complicate the <a href="https://www.benzinga.com/topic/federal-reserve">Federal Reserve's path forward.</a>
According to data released Monday by the Institute for Supply Management (ISM), the Services Purchasing Managers' Index (PMI) edged up from 50.8% in March to 51.6% in April, slightly above economists&#8217; expectations of 50.6. While this reading suggests continued growth, it&#8217;s the slowest expansion in activity since late 2023.
<h3 class="wp-block-heading">Pricing Pressures Intensify Despite Tepid Growth</h3>
ISM's subindex for prices paid, a key inflation gauge, jumped sharply from 60.9% in March to 65.1% in April, reaching the highest level since February 2023. 
This spike reflects intensifying cost pressures across the service economy, driven partly by rising import prices and the pass-through effects of tariffs.
&#8220;Regarding tariffs, respondents cited actual pricing impacts as concerns, more so than uncertainty and future pressures," said Steve Miller, chair of ISM's Services Business Survey Committee.
 "Respondents continue to mention federal agency budget cuts as a drag on business, but overall, results are improving."
The index for new orders rose from 50.4% to 52.3%, while the employment component climbed from 46.2% to 49% — still signaling contraction, but a less severe one.
 Business activity, however, moderated from 55.9 to 53.7, its softest growth pace since January, though it still marked the 59th consecutive month of expansion.
<h3 class="wp-block-heading">S&amp;P Global Flags Stalling Momentum, Stagflation Risks</h3>
S&amp;P Global&#8217;s separate reading on the U.S. services sector painted a less optimistic picture. 
The firm downwardly revised its final Services PMI for April from a preliminary estimates of 51.4 points to 50.8 points, a steep decline from March&#8217;s 54.4 and the lowest since November 2022.
"While tariff announcements mean manufacturing dominates the news, a worrying backstory is developing in the vastly larger services economy," said Chris Williamson, chief business economist at S&amp;P Global. 
"Business activity and hiring have come closer to stalling in April amid plunging business confidence."
Williamson indicated that services exports are falling at their fastest rate since 2022, while domestic demand appears to be softening. 
He added that tariffs are pushing up input costs, especially in consumer-facing sectors like restaurants and hospitality, and warned of the growing threat of stagflation, a toxic mix of stagnant growth and rising inflation.
S&amp;P Global's Composite PMI, which blends manufacturing and services activity to gauge overall private-sector performance, was also revised down from 51.2 to 50.6 in April. 
That marked the weakest expansion since December 2023 and brought the index dangerously close to the 50 threshold that separates growth from contraction.
<h3 class="wp-block-heading">Market Reactions</h3>
Stocks remained broadly unaltered following the PMI releases. 
The S&amp;P 500 index held losses of 0.5%, trading at 5,655 points by 10:20 a.m. ET, potentially ending a 9-day winning streak. The Nasdaq 100 — as tracked by the Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) — slipped 0.7%, dipping below the 20,000 mark, while the Dow Jones Industrial Average trimmed earlier losses to trade down 0.2%.
Within the S&amp;P 500, United Airlines Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>), Delta Air Lines Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) and EQT Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) were top gainers, each up around 3%. 
On the downside, Zimmer Biomet Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>), Tyson Foods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) and ON Semiconductor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) were among the steepest losers, all sliding roughly 9% on the session.
The U.S. dollar index – as tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) – trimmed losses after the PMI reports, as higher price pressures led traders to scale back bets on Federal Reserve rate cuts. Meanwhile, the 10-year Treasury yield rose by 4 basis points to 4.35%.
According to CME Group FedWatch, now there is only a 29% chance of a 25-basis-point cut by June, down from 35% on Friday.
Read now: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45192936/wall-street-veteran-investor-lowers-recession-risk-as-us-china-trade-war-cools">Wall Street Veteran Investor Lowers Recession Risk As US-China Trade War Cools</a></li>
</ul>
Photo: Shutterstock

PowerShares DB US Dollar Index Bullish Fund

Services Activity Barely Expands In April As Price Pressures Spike To Over 2-Year Highs: 'A Worrying Backstory Is Developing'

WIIM

Zimmer Biomet Holdings shares are trading lower after the company lowered its FY25 guidance.

Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) lowers FY2025 Adj EPS guidance from $8.15-$8.35 to $7.90-$8.10 vs $8.19 analyst estimate. Raises FY2025 sales outlook from $7.76 billion-$7.95 billion to $8.12 billion-$8.31 billion vs $7.91 billion estimate.

Zimmer Biomet Holdings Lowers FY2025 Adj EPS Guidance from $8.15-$8.35 to $7.90-$8.10 vs $8.19 Est; Revenue for 2025 FY is expected to up by 5.7% - 8.2% YoY

Press Releases

Paragon 28 Announces Expiration of HSR Act Waiting Period for Pending Acquisition by Zimmer Biomet Under HSR Act

Zimmer Biomet Receives CE Mark Approval for RibFix Advantage® Fixation System

PARAGON 28 INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Paragon 28, Inc. - FNA

Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2025 Financial Results

Zimmer Biomet Completes Acquisition of Paragon 28

Zimmer Biomet Announces First Quarter 2025 Financial Results

Zimmer Biomet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Zimmer Biomet Appoints Kevin Thornal as Group President, Global Businesses and the Americas

Dividends

Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2025

Legal

Treace Files Patent Infringement Suit Against Zimmer Biomet to Protect Lapiplasty® Bunion Technology

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Comments

Zimmer Biomet Holdings

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO